Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?
Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?
In Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), B-cell depletion therapy using rituximab results in variable clinical responses between individuals, which likely relates to variable B-cell depletion in the presence of immune defects. Outcomes in clinical trials with other type I anti-CD20 mAbs, ocrelizumab and ofatumumab, are comparable to rituximab. A mechanistically different type II mAb, obinutuzumab (OBZ), with greater capacity for B-cell depletion, has recently entered clinical trials in SLE. Here we consider whether type II anti-CD20 mAbs will provide mechanistic advantages to overcome the disease-related immune defects in autoimmune diseases such as SLE.
1330-1338
Reddy, Venkat
615826e9-84f3-4053-8ce6-26a2eb214bdc
Dahal, Lekh N.
1e993a7a-b007-4187-82ea-e28dd3920b66
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Leandro, Maria
47412987-6937-4a86-aac9-42f42b669c1c
21 August 2016
Reddy, Venkat
615826e9-84f3-4053-8ce6-26a2eb214bdc
Dahal, Lekh N.
1e993a7a-b007-4187-82ea-e28dd3920b66
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Leandro, Maria
47412987-6937-4a86-aac9-42f42b669c1c
Reddy, Venkat, Dahal, Lekh N., Cragg, Mark S. and Leandro, Maria
(2016)
Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?
Drug Discovery Today, 21 (8), .
(doi:10.1016/j.drudis.2016.06.009).
(PMID:27343722)
Abstract
In Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), B-cell depletion therapy using rituximab results in variable clinical responses between individuals, which likely relates to variable B-cell depletion in the presence of immune defects. Outcomes in clinical trials with other type I anti-CD20 mAbs, ocrelizumab and ofatumumab, are comparable to rituximab. A mechanistically different type II mAb, obinutuzumab (OBZ), with greater capacity for B-cell depletion, has recently entered clinical trials in SLE. Here we consider whether type II anti-CD20 mAbs will provide mechanistic advantages to overcome the disease-related immune defects in autoimmune diseases such as SLE.
Text
DRUDIS-D-16-00044 submitted manuscript.pdf
- Accepted Manuscript
More information
Accepted/In Press date: 22 June 2016
e-pub ahead of print date: 22 June 2016
Published date: 21 August 2016
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 403213
URI: http://eprints.soton.ac.uk/id/eprint/403213
ISSN: 1359-6446
PURE UUID: eab2210c-7487-4ecb-ac15-bc9f34923b22
Catalogue record
Date deposited: 28 Nov 2016 14:52
Last modified: 16 Mar 2024 02:58
Export record
Altmetrics
Contributors
Author:
Venkat Reddy
Author:
Lekh N. Dahal
Author:
Maria Leandro
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics